Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
516.69
-3.40 (-0.65%)
At close: Apr 28, 2026, 4:00 PM EDT
516.69
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:15 PM EDT
Madrigal Pharmaceuticals Revenue
In the year 2025, Madrigal Pharmaceuticals had annual revenue of $958.40M with 432.05% growth. Madrigal Pharmaceuticals had revenue of $321.08M in the quarter ending December 31, 2025, with 210.77% growth.
Revenue (ttm)
$958.40M
Revenue Growth
+432.05%
P/S Ratio
12.40
Revenue / Employee
$1,047,435
Employees
915
Market Cap
11.85B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Arrowhead Pharmaceuticals | 1.09B |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
| Axsome Therapeutics | 638.50M |
MDGL News
- 6 days ago - Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 - GlobeNewsWire
- 7 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - PRNewsWire
- 2 months ago - Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs - GlobeNewsWire